Heart failure (HF) remains a significant health problem despite advances in diagnosis and treatment options. Malnutrition and increased inflammation predict poor disease prognosis. The parameters of the Naples prognostic score (NPS) include albumin, total cholesterol, neutrophil-lymphocyte ratio (NLR), and lymphocyte-monocyte ratio (LMR). We aimed to assess the potential of NPS as a predictor of long-term mortality in patients with HF. A total of 1728 patients with HF who applied to our center between 2018 and 2022 were included in this study. The NPS was computed and the patients were divided into three groups according to their NPS values as follows: NPS = 0 (Group 1), NPS = 1-2 (Group 2), and NPS = 3-4 (Group 3). We also evaluated the association between NPS value and HF mortality. The patients were followed for a mean follow-up duration of 30 months. The mortality rate was 8.3% (145 patients). We carried out Model-1 and -2 Cox regression analyses to identify long-term mortality determinants. Model-2 was constructed by adding NPS to Model-1. NPS was significantly associated with HF mortality (Hazard Ratio: 2.194, 95% Confidence Interval: 1.176-4.091, p = 0.014). According to the Kaplan-Meier plot and log-rank analyses, there was a statistically significant difference in the long-term mortality of patients with HF and their NPS values for the entire cohort. Based on our findings, NPS showed promise as an independent predictor of long-term mortality in individuals with HF.

The systemic immune-inflammation index (SII), a novel marker derived from the combination of platelet, neutrophil, and lymphocyte counts, has been linked to unfavorable clinical outcomes in various malignancies and inflammatory conditions. This study aims to assess the association between SII and disease prognosis in patients with heart failure with reduced ejection fraction (HFrEF). A total of 521 patients (72% male; mean age: 67 ± 13 years) diagnosed with HFrEF were retrospectively analyzed. Clinical, demographic, laboratory, and echocardiographic data were collected. SII scores were calculated for all patients, and their prognostic significance and clinical outcomes were evaluated. 521 patients were analyzed. According to current findings, all-cause mortality occurred in 87 patient during the follow-up period. The mean SII in the mortality group was higher than in the survivors and was found to be statistically significant. (878.57 vs. 643.65; p = 0.003, respectively) In the multivariable regression model SII was found to be an independent risk factor for mortality. (p = 0.031) The AUC of SII for mortality prediction was 0.602 (95% CI = 0.531–0.673), the cut-off value was 729, and the sensitivity and specificity were 59.3% and 59.6% (p = 0.003). This study demonstrates a significant association between SII and both survival and prognosis in patients with HFrEF. Notably, the SII index was found to be an independent predictor of mortality in this patient population.

Acute coronary syndromes (ACS) are one of the most common causes of morbidity and mortality worldwide. Primary percutaneous coronary intervention (pPCI) is the main treatment strategy to restore myocardial perfusion. However, the no-reflow phenomenon (NRP) may block coronary flow. The present study focused on assessing and contrasting predictive parameters for NRP in ACS patients. Our research is a retrospective analysis. We assessed the parameters significantly associated with NRP using Cox regression and Receiver operating characteristic (ROC) Curve analysis. The study included 5122 patients who met the criteria. The average age of the patients was 63.9 + 13.2, and 74.4% were male. It was observed that NRP developed in 1.8% of all patients. Age, hemoglobin (Hb), white blood cell (WBC), glucose and low density lipoprotein cholesterol (LDL-C) were determined to be independent predictors of NRP. The power of these parameters to predict NRP was similar, and WBC was the most predictive (Area Under Curve (AUC): 0.605 95% CI: 0.539–0.671, P = .001). We believe that the use of these simple, practical, and routinely used hematological and biochemical parameters will help us predict the risk of developing NRP before pPCI. This information should improve management.

Our study compared the effect of P2Y12 receptor inhibitors in combination with abciximab on clinical outcomes in patients with acute coronary syndrome (ACS). Our study is retrospective, consisting of 852 consecutive ACS patients who presented to our clinic between 2015 and 2021, underwent primary percutaneous coronary intervention (PCI), and received abciximab in addition to dual antiplatelet therapy. The P2Y12 receptor inhibitors were compared in terms of in-hospital and 1-year major adverse cardiac events (MACE), and clinically significant in-hospital and 1-year bleeding complications. The patients' mean age was 60.4 ± 11 years, and 702 (82.4%) were male. In-hospital MACE, in-hospital mortality, 1-year MACE, and 1-year mortality were significantly higher in the clopidogrel group compared to the ticagrelor group. There was no significant difference in the development of in-hospital and 1-year bleeding between clopidogrel and the more potent P2Y12 receptor inhibitors. According to the BARC score, there was no difference in major bleeding between ticagrelor and clopidogrel (p = 0.641), but minor bleeding was significantly lower in the ticagrelor group (p < 0.001). In logistic regression analysis, the 1-year MACE rate was lower in the potent P2Y12 receptor inhibitors group compared to clopidogrel. At the same time, no association was found with short- and long-term mortality, bleeding, or in-hospital MACE. In our study, potent P2Y12 receptor inhibitors combined with abciximab decreased 1-year MACE without significantly increasing bleeding in ACS patients undergoing PCI compared to clopidogrel. This study suggests that potent P2Y12 receptor inhibitors can be safely used with abciximab, considering the bleeding risk.

Heart failure (HF) is a chronic progressive clinical condition characterized by structural or functional impairment of the ventricles. The prevalence of HF is increasing, and it continues to be a significant cause of morbidity and mortality. Liver involvement during fibrosis in HF patients is associated with adverse clinical outcomes. Our study aimed to evaluate the relationship between noninvasive liver fibrosis indices and HF mortality. Our study was a retrospective analysis of patients with HF admitted to our hospital between 2017 and 2023. Patients were followed up until 2024 and divided into 2 groups according to mortality. The patients’ liver fibrosis indices were calculated, and Cox regression analysis was performed to identify the independent predictors of mortality. Their ability to predict mortality was assessed using receiver operating characteristic Curve analysis, and the areas under the curve were compared. Our study included 2029 patients with HF. The mean follow-up period was 1655 days. The mortality rate was 9.5% (N = 193). The aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio was not a predictor of HF mortality, whereas APRI and FIB-4 index were independent predictors of HF mortality. According to receiver operating characteristic curve analysis, the FIB-4 score was superior to the APRI in predicting mortality. The APRI had a specificity of 93.4% at a cutoff value of 1.0. The FIB-4 Score had a sensitivity of 89.6% at a cutoff value of 1.0. Our study found that AST/ALT ratio did not predict HF mortality. However, our study found that the FIB-4 score was associated with mortality in all types of HF, and the APRI was associated with mortality in HFrEF and HFmrEF. These parameters can be calculated easily and practically from routine examinations and can be used in HF follow-up and prognosis estimation.

Introduction: Implantable cardioverter defibrillator (ICD) and pacemaker (PM) implantation may lead to anxiety and depression, which may reduce patients' quality of life. The aim of our study was to compare depression and anxiety following device implantation.Methods: This prospective study was conducted on 202 patients admitted to our hospital with ICD and PM implants between January 2024 and January 2025.Results: The prevalence of anxiety in PM and ICD recipients was 25.9% and 38.8%, respectively. There was a significant difference in anxiety in ICD patients (< 0.001). In terms of depression, the results in the PM and ICD groups were 18.9 and 38.9, respectively. The results showed a significant difference in the prevalence of depression between PM and ICD recipients. The tendency toward depression was statistically significant in both device recipients (PM; p = 0.008, ICD; p < 0.001).Conclusion: Considering the prevalence of anxiety and depression, it seems necessary to pay closer attention to the anxiety and depression states of patients who have been treated with PM and ICD devices and to provide more widespread education to these patients.